Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine

Sasso, Bruna Lo; Agnello, Luisa; Giglio, Rosaria Vincenza; Gambino, Caterina Maria; Ciaccio, Anna Maria; Vidali, Matteo; Ciaccio, Marcello

doi:10.1038/s41598-022-12750-z

Cited by 34 publications

(33 citation statements)

References 40 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Screening of vaccinated individuals represents a valuable tool for unravel the type and duration of the protective immune response, and for estimating the necessity of a booster dose, helping thus the health decision authorities in implementing important actions for controlling the pandemic and improve the vaccination scheme 39 . At least for a while, screening humoral immune response in vaccinated and infected people is very important to assess persistence of immunity in COVID-19, and evaluate the protective power of the SARS-CoV-2 antibodies 40 . In particular, serological testing could best catch the time-point when protective antibody levels begin to decrease and therefore this test should be included into vaccine effectiveness studies 39 .…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers

Zurac

Vlădan

Dincă

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Waning of the immune response upon vaccination in SARS-CoV-2 infection is an important subject of evaluation in this pandemic, mostly in healthcare workers (HCW) that are constantly in contact with infected samples and patients. Therefore, our study aimed to establish the specific humoral response of specific IgG and IgA antibodies upon vaccination, during the second year of pandemic and evaluating the booster shot with the same vaccine type. A group of 103 HCW with documented exposure to the virus were monitored for specific IgG and IgA levels prior to vaccination, after the first vaccination round, during the following 8 months and after the booster shot with the same vaccine type. After 8 months post-vaccination the humoral response in both IgG and IgA decreased, 2.4 times for IgG, and 2.7 times for IgA. Although the antibodies levels significantly decreased, no documented infection was registered in the group. After the booster shot, the entire group, displayed IgG increased levels, immediately after booster followed by the increase in specific IgA. IgG levels post-second round of vaccination are statistically higher compared to the first round, while IgA is restored at the same levels. Within the vaccination or booster routine for a multiple waves’ pandemic that is generating new virus variants, populational immunity remains an important issue for future implementation of prevention/control measures.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers

Zurac

Vlădan

Dincă

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The analysis of these three cases of antibody changes over time during the COVID-19 pandemic provides students training material and allows them to observe and control the effects of treatment-including when to administer the third or subsequent dose of the vaccine at the appropriate time for the natural course of the disease [25,26].…”

Section: Discussionmentioning

confidence: 99%

“…We call this effect vanishing antibodies. Another illness with a new variant of the SARS-CoV-2 virus can stimulate a new response to a different level [24][25][26].…”

Section: Introductionmentioning

confidence: 99%

A New Set-up of Vanishing Antibodies: A Biennial Follow-up of Three Different Clients’ Humoral Responses Against Sars-Cov-2 After Systemic Vaccination in an Oncology Hospital in Poland

Kosiorek¹,

Stróż²,

Hryniewicz³

et al. 2022

Preprint

View full text Add to dashboard Cite

The humoral response of the COVID-19 vaccine varies from person to person. It largely depends on prior SARS-CoV-2 infection, obtaining an adequate immune response, and leaving a trace of changing antibody concentration over time. We retrospectively analyzed three clinical cases from selected patients and employees of the oncology hospital. All mild COVID-19 convalescents received the BNT162b2-Comirnaty mRNA vaccine three times. The levels of SARS-CoV-2 IgM- and IgG-specific antibodies, as well as S-RBD antibodies, were analyzed for approximately two years. The concentration of antibodies was assessed in the laboratory using the chemiluminescent immunoassay CLIA, MAGLUMI. Results: (1) Active autoimmune disease stabilized the level of IgG-specific antibodies after systemic mRNA vaccination for at least six months. (2) Post-vaccination IgG and S-RBD levels decreased when vaccination was performed within three months of onset. (3) The booster dose (third dose) administered only increased the S-RBD antibody levels. Declining IgG-specific antibodies were observed. (4) The S-RBD IgG levels were not correlated with the SARS-CoV-2 IgG levels in the vaccinated convalescents. (5) Subsequent reinfection with SARS-CoV-2 after vaccination three times released a more significant specific antibody response. Based on the collected data, we suggest that monitoring S-RBD antibodies is sensitive but not equivalent to a specific humoral response for SARS-CoV-2 IgG. We suggested that administering at least three doses of the mRNA vaccine should serve as the basis for immunization. The three-month interval may be the best alternative to an immunization schedule for non-immunocompromised people.

show abstract

“…CLIA has several advantages over ELISA, such as full automation, cost-effectiveness, reproducibility, fast and precise measurement. Additionally, literature evidence shows that CLIA immunoassays have high diagnostic sensitivity and specificity for detecting anti-SARS-CoV-2 antibody levels [ 5 , 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

“…The evaluation of anti-SARS-CoV-2 antibody levels is helpful for assessing individual protection against SARS-CoV-2 infection [5][6][7][8][9][10][11][12]. Thus, manufacturers have invested heavily in this sector by developing and marketing in a very short time numerous assays with highly different characteristics in terms of analytical method and antibodies detected.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the analytical performance of three chemiluminescence serological assays for detecting anti-SARS-CoV-2 antibodies

et al. 2022

View full text Add to dashboard Cite

The serology surveillance of SARS-CoV-2 antibodies represents a useful tool for monitoring protective immunity in the population. We compared the performance of three SARS-CoV-2 antibody serological immunoassays in 600 vaccinated subjects after the BNT162b2 mRNA COVID-19 vaccine. All serum samples were evaluated by three different immunoassays for detecting anti-SARS-COV-2 antibodies. All SARS-CoV-2 antibody serological immunoassays could detect, when present, a post-vaccine humoral immune response. Median (interquartile range, IQR) anti-S-RBD IgG, Access SARS-CoV-2 IgG (1st IS) and Access SARS-CoV-2 IgG II levels of the subjects investigated were, respectively, 687 BAU/mL (131–2325), 419 IU/mL (58–1091) and 104 AU/mL (14–274). By studying a cohort of unvaccinated subjects, without previous COVID-19 infection, we found a high specificity for all methods. A high correlation was found between IgG titres. Considering the kinetics of subjects with multiple doses, we observed that percentage decreasing gradients were comparable across methods. Our results suggest that all the SARS-CoV-2 antibody serological immunoassays evaluated in this study are suitable for monitoring IgG titers over time. This study contributes to a better understanding of antibody response in vaccinated subjects using some currently available assays.

show abstract

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine

Cited by 34 publications

References 40 publications

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers

A New Set-up of Vanishing Antibodies: A Biennial Follow-up of Three Different Clients’ Humoral Responses Against Sars-Cov-2 After Systemic Vaccination in an Oncology Hospital in Poland

Evaluation of the analytical performance of three chemiluminescence serological assays for detecting anti-SARS-CoV-2 antibodies

Contact Info

Product

Resources

About